.gif) VIARTIS
|
||
|
|
PARKINSON'S DISEASE NEWS
|
|
|
13th June 2011 - News release LCIG CLINICAL TRIAL DATA FOR PARKINSON'S DISEASE Abbott have provided details of a Phase 3 clinical trial of
LCIG in
Parkinson's Disease. LCIG is levodopa-carbidopa intestinal gel. Levodopa-carbidopa
is the same combination used in Sinemet. LCIG is infused directly and
continuously during daytime hours into the small intestine via a portable pump
connected to a surgically-implanted gastric tube. It was thought that continuous
delivery may help reduce peaks in drug levels
Adverse events occurred in 87% of patients, and appeared to be largely related to the surgical procedure. The most common adverse events were : abdominal pain (30%), complications of device insertion (21%), procedural pain (17%), constipation (13%), nausea (13%), excessive granulation tissue (13%), fall (10%), dyskinesia (10%), insomnia (10%), post-operative wound infection (10%), and anxiety (10%). The most severe complications from surgery were : abdominal inflammation (3%), and gas or air in the peritoneal cavity (5%). For more information go to the News release. For more current news go to Parkinson's Disease News.
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News, please merely e-mail [email protected] with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose. LOW RESOLUTION VERSION : There is a low resolution version of PARKINSON'S DISEASE NEWS INTENDED FOR THOSE PEOPLE THAT EITHER : use 800x600 resolution on their monitors, or have eyesight difficulties, or slow Internet speeds. GO TO LOW RESOLUTION VERSION Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided, as well as links to the complete abstracts and news reports
|
||
|
|
||
.gif) |
||
| ©2006-2011 Viartis | ||
| 2015-04-27 14:20:02 | ||
| [email protected] | ||
due
to the inconsistent absorption that happens with orally consumed drugs. After 12
weeks in to the 54 week trial, patients reported an average of 3.9 fewer hours
of "off" time and 4.6 more hours of "on" time without dyskinesias. Self
reporting after surgery is very prone to placebo effect, yet figures for a
placebo were not provided, thus preventing an assessment of how much actual
improvement there was beyond that of a placebo. 
